Association of the SLC5A2 rs9934336 polymorphism with fasting plasma glucose in patients with type 2 diabetes mellitus
Main Article Content
Abstract
Given the critical role of genetic factors in glycemic control, this study investigated the association between the SLC5A2 rs9934336 polymorphism and fasting plasma glucose (FPG) levels in Vietnamese patients with type 2 diabetes mellitus (T2DM). A cross-sectional study was conducted on 123 diagnosed T2DM patients at Phu Nhuan District Hospital from July 2025 to November 2025. The SLC5A2 rs9934336 genotypes were identified using real-time polymerase chain reaction. FPG levels were compared across genotype groups, and multivariate linear regression was used to adjust for confounding factors. The frequencies of the GG, GA, and AA genotypes were 26.8%, 65.9%, and 7.3%, respectively. The GA+AA group exhibited significantly higher median FPG levels compared to the GG group (p = 0.013). In the multivariate regression analysis, each A allele was associated with a 10.3% increase in FPG levels after adjustment for confounders and False Discovery Rate (FDR) correction (p = 0.018). In conclusion, the SLC5A2 rs9934336 polymorphism is associated with FPG levels in T2DM patients, suggesting a potential role in glycemic regulation via the SGLT2 transporter.
Article Details
Keywords
rs9934336 polymorphism, SLC5A2 gene, type 2 diabetes mellitus, association, fasting plasma glucose
References
2. Wright EM, Loo DD, Hirayama BA. Biology of human sodium glucose transporters. Physiological reviews. 2011; 91(2): 733-94. doi:10.1152/physrev.00055.2009.
3. Nguyen QT, Tran AV, Nguyen BT, Nguyen HT, Thai NTH, Phan HH. Lipid profile and apolipoprotein B serum levels in Vietnamese population with newly diagnosed elevated LDL-c and the association with the single nucleotide variant rs676210: A cross-sectional study. 2025; 9:e76850. doi:10.2196/76850.
4. Enigk U, Breitfeld J, Schleinitz D, et al. Role of genetic variation in the human sodium-glucose cotransporter 2 gene (SGLT2) in glucose homeostasis. Pharmacogenomics. 2011; 12(8): 1119-26. doi:10.2217/pgs.11.69.
5. Drexel H, Leiherer A, Saely Christoph H, et al. Are SGLT2 polymorphisms linked to diabetes mellitus and cardiovascular disease? Prospective study and meta-analysis. Bioscience Reports. 2019; 39(8): 1-10. doi:10.1042/bsr20190299.
6. Committee ADAPP. 2. Diagnosis and Classification of Diabetes: Standards of Care in Diabetes-2025. Diabetes care. 2024; 48(Supplement_1): 27-49. doi:10.2337/dc25-S002.
7. Bộ Y Tế. Hướng dẫn chẩn đoán và điều trị đái tháo đường típ 2. Quyết định số 5481/QĐ-BYT. 2020:1-77.
8. Chowdhury MZI, Turin TC. Variable selection strategies and its importance in clinical prediction modelling. Family medicine and community health. 2020; 8(1): e000262. doi:10.1136/fmch-2019-000262.
9. Ughade S. Statistical modeling in epidemiologic research: Some basic concepts. Clinical Epidemiology and Global Health. 2013;1(1): 32-36. doi:10.1016/j.cegh.2013.01.003.
10. Tonin G, Goričar K, Blagus T, Janež A, Dolžan V, Klen J. Genetic variability in sodium-glucose cotransporter 2 and glucagon-like peptide 1 receptor effect on glycemic and pressure control in type 2 diabetes patients treated with SGLT2 inhibitors and GLP-1RA in the everyday clinical practice. Frontiers in endocrinology. 2025; 16: 1547920. doi:10.3389/
fendo.2025.1547920.